ACLX
ACLX
NASDAQ · Biotechnology

Arcellx Inc

$115.07
+0.04 (+0.03%)
As of May 8, 9:56 PM ET ·
Financial Highlights (FY 2026)
Revenue
23.16M
Net Income
-237,880,943
Gross Margin
Profit Margin
-1,027.3%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 38.6% 38.6% 38.6%
Operating Margin -1,135.6% 7.8% 8.0% 6.7%
Profit Margin -1,027.3% 5.0% 4.8% 5.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 23.16M 2.26B 2.06B 2.46B
Gross Profit 873.66M 796.13M 951.80M
Operating Income -262,971,050 177.50M 165.04M 165.78M
Net Income -237,880,943 113.46M 99.51M 136.19M
Gross Margin 38.6% 38.6% 38.6%
Operating Margin -1,135.6% 7.8% 8.0% 6.7%
Profit Margin -1,027.3% 5.0% 4.8% 5.5%
Rev Growth +18.8% +20.4% -8.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 1.10B 1.29B 1.09B
Total Equity 1.38B 1.34B 1.34B
D/E Ratio 0.80 0.97 0.82
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -256,035,462 251.62M 213.71M 234.58M
Free Cash Flow 62.68M 52.56M 67.17M